Apellis Pharmaceuticals (APLS) PT Lowered to $38 at Mizuho

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. IVBIY

Go back to Apellis Pharmaceuticals (APLS) PT Lowered to $38 at Mizuho

Citi Reiterates Buy Rating on Apellis Pharmaceuticals (APLS)

October 28, 2024 5:42 AM EDT

Citi analyst Yigal Nochomovitz reiterated a Buy rating and $63.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).

The analyst comments "At ASN, APLS shared additional Ph3 data for pegcetacoplan in C3G/IC-MPGN, reiterating an overall proteinuria reduction of ~68% and clinically meaningful proteinuria... More